A novel and successful strategy to predict survival

American Journal of Surgical Pathology

Volumn 38, Issue 3, 2014, Pages 325-332

  Fleischmann, Achim ^a   Thalmann, George N ^a   Perren, Aurel ^a   Seiler, Roland ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

bladder cancer; neoadjuvant chemotherapy; tumor regression grade

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER; BLADDER TUMOR; CANCER GRADING; CYSTECTOMY; DRUG EFFECT; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MIDDLE AGED; MORTALITY; OBSERVER VARIATION; PATHOLOGY; PREDICTIVE VALUE; REMISSION; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR INVASION; UROTHELIUM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84894488328     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000142     Document Type: Article

References (30)

1. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - A homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690-696
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-Term results in 1,054 patients. J Clin Oncol. 2001;19:666-675
3. ABC. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-Analysis. Lancet. 2003;361:1927-1934
4. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-Term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171-2177
5. Bajorin DF, Herr HW. Kuhn's paradigms: Are those closest to treating bladder cancer the last to appreciate the paradigm shift?. J Clin Oncol. 2011;29:2135-2137
6. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866
7. Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 2012;118:72-81
8. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol. 2004;45:297-303
9. Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic downstaging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series. Cancer. 2009;115:792-799
10. Sobin LH, Wittekind C, International Union Against Cancer. TNM Atlas. 7th ed. New York: Wiley-Lyss Inc.; 2009
11. Morgan MJ, Koorey DJ, Painter D, et al. Histological tumour response to pre-operative combined modality therapy in locally advanced rectal cancer. Colorectal Dis. 2002;4:177-183
12. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752-760
13. Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Ann Surg. 2011;253:934-939
14. Fareed KR, Ilyas M, Kaye PV, et al. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology. 2009;55:399-406
15. Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22:1555-1563
16. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686
17. Fleischmann A, Thalmann GN, Markwalder R, et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol. 2005;23:2358-2365
18. Studer UE, Danuser H, Merz VW, et al. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol. 1995;154:49-56
19. Perez RO, Habr-Gama A, dos Santos RM, et al. Peritumoral inflammatory infiltrate is not a prognostic factor in distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2007;11:1534-1540
20. Carrillo R, Candia A, Rodriguez-Peralto JL, et al. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol. 1997;28:160-165
21. Gervaz P, Rubbia-Brandt L, Andres A, et al. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: A comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol. 2010;17:2714-2719
22. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscleinvasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol. 2011;59:1009-1018
23. Bauer TW, Spitz FR. Adjuvant and neoadjuvant chemoradiation therapy for primary colorectal cancer. Surg Oncol. 1998;7:175-181
24. Mooney MM. Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. J Surg Oncol. 2005;92:230-238
25. Niegisch G, Albers P. Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. Curr Opin Urol. 2011;21:434-439
26. Perdona S, Autorino R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: A multi-institutional, long-Term experience. Cancer. 2008;112:75-83
27. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: Evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185:72-78
28. Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: A Canadian multicentre experience. BJU Int. 2010;108:539-545
29. Grossman HB, Tangen CM, Cordon-Cardo C, et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group Study. Oncol Rep. 2006;16:807-810
30. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res. 2001;7: 2168-2181